OS Therapies (OSTX) Achieves Key Milestone As Patient Enrolment Concludes
Shares of OS Therapies Incorporated (NYSE: OSTX) experienced a significant rise following the completion of patient enrolment in its AOST-2121 clinical trial. As of the latest trading session, OSTX stock surged by 11.06%, reaching $3.25. Final Evaluations and FDA Engagement Today, OS Therapies (OSTX) announced that the final patient, designated as Patient #41, has successfully …
OS Therapies (OSTX) Achieves Key Milestone As Patient Enrolment Concludes Read More »